Evidence map›Paper›PMID 32405548›Full record

ArticleHeliyon2020

Antineoplastic activity of a novel ruthenium complex against human hepatocellular carcinoma (HepG2) and human cervical adenocarcinoma (HeLa) cells.

Carlos Eduardo Alves de Souza, Amanda do Rocio Andrade Pires, Carolina Riverin Cardoso, Rose Maria Carlos, Silvia Maria Suter Correia Cadena, Alexandra Acco

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Carlos Eduardo Alves de SouzaDepartment of Pharmacology, Federal University of Parana, Curitiba, Brazil.
Amanda do Rocio Andrade PiresDepartment of Biochemistry and Molecular Biology, Federal University of Parana, Curitiba, Brazil.
Carolina Riverin CardosoDepartment of Chemistry, Federal São Carlos University, São Carlos, Brazil.
Rose Maria CarlosDepartment of Chemistry, Federal São Carlos University, São Carlos, Brazil.
Silvia Maria Suter Correia CadenaDepartment of Biochemistry and Molecular Biology, Federal University of Parana, Curitiba, Brazil.
Alexandra AccoDepartment of Pharmacology, Federal University of Parana, Curitiba, Brazil.
Universidade Federal do Paraná · BRUniversidade Federal de São Carlos · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel metal complexes have received much attention recently because of their potential anticancer activity. Notably, ruthenium-based complexes have emerged as good alternatives to the currently used platinum-based drugs for cancer therapy, with less toxicity and fewer side effects. The beneficial properties of Ru, which make it a highly promising therapeutic agent, include its variable oxidative states, low toxicity, and high selectivity for cancer cells. The present study evaluated the cytotoxic effects of a ruthenium complex, namely

Indexed as

BiochemistryHeLa cells: Cell respirationHepatocellular carcinomaHepG2 cellsMetabolismOncologyPharmaceutical chemistryPharmacologyRuthenium complexToxicology

Identifiers

PMID32405548
PMCPMC7210510
OpenAlexW3021506523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.